Breast cancer outcome in relation to bone mineral density and bisphosphonate use: a sub-study of the DATA trial

the Dutch Breast Cancer Research Group (BOOG)

Research output: Contribution to journalArticleAcademicpeer-review

3 Citations (Scopus)
3 Downloads (Pure)

Abstract

Purpose: The phase III DATA study compared 6 and 3 years of adjuvant anastrozole following 2–3 years of tamoxifen in postmenopausal breast cancer patients. This pre-planned side-study assessed the relationship between a reduced bone mineral density (BMD) and distant recurrence-free survival (DRFS), and evaluated the effect of bisphosphonates on DRFS. Methods: We selected all patients with a BMD measurement within 3 years after randomisation (landmark) without any DRFS events. Kaplan–Meier methods and Cox proportional hazards models were used for analyses. Results: Of 1860 eligible patients, 1142 had a DEXA scan before the landmark. The BMD was normal in 436 (38.2%) and showed osteopenia in 565 (49.5%) and osteoporosis in 141 (12.3%) patients. After a median follow-up of 5.0 years from the landmark, neither osteopenia nor osteoporosis (compared with normal BMD) were associated with DRFS in both the 6-year [osteopenia HR 0.82 (95% CI 0.45–1.49), osteoporosis HR 1.10 (95% CI 0.26–4.67)] and the 3-year arm [osteopenia HR 0.75 (95% CI 0.40–1.42), osteoporosis HR 1.86 (95% CI 0.43–8.01)]. Moreover, bisphosphonate use did not impact DRFS. Conclusion: No association was observed between a reduced BMD and DRFS. Neither did we observe an impact of bisphosphonates on DRFS.

Original languageEnglish
Pages (from-to)675-685
Number of pages11
JournalBreast Cancer Research and Treatment
Volume180
Issue number3
DOIs
Publication statusPublished - 1 Apr 2020

Bibliographical note

Funding Information:
This study was funded by AstraZeneca NL, ClinicalTrials.gov number, NCT00301457.

Funding Information:
IEGvH, SCL and ACPS report institutional grants from AstraZeneca during the conduct of the study. MdB reports research grants from Roche, Eisai, Novartis, Pfizer, and Lily during the conduct of the study; and consultation/speakers fee from Roche, Novartis, and Pfizer. VCGT-H reports consultant/advisory role to Pfizer, Lily, and Novartis, and grants to the institute for research from AstraZeneca, Roche, Novartis, Pfizer, and Lilly during the conduct of the study. FWPJvdB, FLGE, HdG, AH, ALTI, JRK, PGMP, WKdR, MJCvdS, CMS, CHS declare no conflicts of interests.

Funding Information:
We thank Wim A.J.G. Lemmens, Bianca Schalk, and Ton de Haan for their assistance with performing the statistical analyses.

Publisher Copyright:
© 2020, The Author(s).

Fingerprint

Dive into the research topics of 'Breast cancer outcome in relation to bone mineral density and bisphosphonate use: a sub-study of the DATA trial'. Together they form a unique fingerprint.

Cite this